SG10201811365RA - Slow-release conjugates of sn-38 - Google Patents
Slow-release conjugates of sn-38Info
- Publication number
- SG10201811365RA SG10201811365RA SG10201811365RA SG10201811365RA SG10201811365RA SG 10201811365R A SG10201811365R A SG 10201811365RA SG 10201811365R A SG10201811365R A SG 10201811365RA SG 10201811365R A SG10201811365R A SG 10201811365RA SG 10201811365R A SG10201811365R A SG 10201811365RA
- Authority
- SG
- Singapore
- Prior art keywords
- slow
- conjugates
- release
- release conjugates
- glucuronate
- Prior art date
Links
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 abstract 1
- 239000002202 Polyethylene glycol Substances 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 238000003379 elimination reaction Methods 0.000 abstract 1
- 229940097042 glucuronate Drugs 0.000 abstract 1
- 229920001223 polyethylene glycol Polymers 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
- A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
- A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
- C08G65/32—Polymers modified by chemical after-treatment
- C08G65/329—Polymers modified by chemical after-treatment with organic compounds
- C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
- C08G65/33396—Polymers modified by chemical after-treatment with organic compounds containing nitrogen having oxygen in addition to nitrogen
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
- C08G65/34—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from hydroxy compounds or their metallic derivatives
- C08G65/48—Polymers modified by chemical after-treatment
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G83/00—Macromolecular compounds not provided for in groups C08G2/00 - C08G81/00
- C08G83/002—Dendritic macromolecules
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Polymers & Plastics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361887111P | 2013-10-04 | 2013-10-04 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201811365RA true SG10201811365RA (en) | 2019-02-27 |
Family
ID=51871275
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201811365RA SG10201811365RA (en) | 2013-10-04 | 2014-10-03 | Slow-release conjugates of sn-38 |
| SG11201602258WA SG11201602258WA (en) | 2013-10-04 | 2014-10-03 | Slow-release conjugates of sn-38 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201602258WA SG11201602258WA (en) | 2013-10-04 | 2014-10-03 | Slow-release conjugates of sn-38 |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US10016411B2 (https=) |
| EP (1) | EP3052101B1 (https=) |
| JP (2) | JP6473145B2 (https=) |
| KR (1) | KR102320753B1 (https=) |
| CN (1) | CN106061483B (https=) |
| AU (2) | AU2014331591B2 (https=) |
| BR (1) | BR112016007410B1 (https=) |
| CA (1) | CA2925132C (https=) |
| DK (1) | DK3052101T3 (https=) |
| ES (1) | ES2759905T3 (https=) |
| MX (1) | MX371201B (https=) |
| SG (2) | SG10201811365RA (https=) |
| TW (1) | TWI716342B (https=) |
| WO (1) | WO2015051307A1 (https=) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK3052101T3 (da) * | 2013-10-04 | 2019-12-16 | Prolynx Llc | Konjugater af sn-38 med langsom frigivelse |
| CN107375288B (zh) * | 2016-05-16 | 2019-08-23 | 博瑞生物医药(苏州)股份有限公司 | 多臂的聚合靶向抗癌偶联物 |
| EP3613792B1 (en) | 2017-04-21 | 2021-02-24 | Bright Gene Bio-Medical Technology Co., Ltd. | Multi-arm targeted anti-cancer conjugate |
| MX2020007306A (es) * | 2018-01-12 | 2020-09-25 | Prolynx Llc | Tratamiento sinergico de cancer. |
| JP7546552B2 (ja) | 2018-09-17 | 2024-09-06 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィア | ポリマーベースの高分子プロドラッグ |
| WO2020206358A1 (en) | 2019-04-05 | 2020-10-08 | Prolynx Llc | Improved conjugation linkers |
| CN114615978A (zh) * | 2019-08-28 | 2022-06-10 | 普罗林科斯有限责任公司 | Dna损伤响应的偶联抑制剂 |
| IL301558A (en) | 2020-09-28 | 2023-05-01 | Fundacio Inst De Recerca Biomedica Irb Barcelona | Peptidic conjugates of sn38 useful in the treatment of cancer |
| US11976196B2 (en) * | 2021-04-14 | 2024-05-07 | Cambridge Crops, Inc. | Silk packaging applications |
| IL315988A (en) | 2022-03-28 | 2024-11-01 | Sant Joan De Deu Hospital | Peptidic water-soluble delivery system of anticancer drugs |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6011042A (en) * | 1997-10-10 | 2000-01-04 | Enzon, Inc. | Acyl polymeric derivatives of aromatic hydroxyl-containing compounds |
| US20040176270A1 (en) * | 2002-07-12 | 2004-09-09 | Biomarin Pharmaceutical Inc. | Use of isocyanate linkers to make hydrolyzable active agent biopolymer conjugates |
| EP1580216B1 (en) | 2002-10-31 | 2014-05-14 | Nippon Kayaku Kabushiki Kaisha | High-molecular weight derivatives of camptothecins |
| US20040247624A1 (en) * | 2003-06-05 | 2004-12-09 | Unger Evan Charles | Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility |
| ES2629696T3 (es) * | 2003-09-17 | 2017-08-14 | Nektar Therapeutics | Profármacos poliméricos multibrazo |
| US7462627B2 (en) | 2006-02-09 | 2008-12-09 | Enzon Pharmaceuticals, Inc. | Multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin for treatment of breast, colorectal, pancreatic, ovarian and lung cancers |
| MX2009002855A (es) * | 2006-09-15 | 2009-03-30 | Enzon Pharmaceuticals Inc | Profarmacos polimericos dirigidos que contienen enlazadores multifuncionales. |
| CA2738807A1 (en) * | 2008-10-21 | 2010-04-29 | Enzon Pharmaceuticals, Inc. | Treatment of neuroblastoma with multi-arm polymeric conjugates of 7-ethyl-10-hydroxycamptothecin |
| JP2012509469A (ja) | 2008-11-18 | 2012-04-19 | バクスター・インターナショナル・インコーポレイテッド | ポリエチレングリコールサンプルの多分散度および/または分子量分布を決定する方法 |
| WO2010138719A1 (en) | 2009-05-28 | 2010-12-02 | Mersana Therapeutics, Inc. | Polyal drug conjugates comprising variable rate-releasing linkers |
| ME03396B (me) * | 2009-11-18 | 2020-01-20 | Nektar Therapeutics | Oblici kisele soli konjugata polimer-lek |
| US8703907B2 (en) * | 2010-05-05 | 2014-04-22 | Prolynx Llc | Controlled drug release from dendrimers |
| EP2566335B1 (en) | 2010-05-05 | 2016-06-29 | Prolynx Llc | Controlled release of active compounds from macromolecular conjugates |
| JP2012000072A (ja) * | 2010-06-18 | 2012-01-05 | Japan Health Science Foundation | 新規な抗フィブリン抗体 |
| TW201215412A (en) * | 2010-08-30 | 2012-04-16 | Sun Pharma Advanced Res Co Ltd | Stable pharmaceutical composition |
| WO2012088282A1 (en) * | 2010-12-21 | 2012-06-28 | Nektar Therapeutics | Multi-arm polymeric prodrug conjugates of pemetrexed-based compounds |
| WO2013036857A1 (en) * | 2011-09-07 | 2013-03-14 | Prolynx Llc | Sulfone linkers |
| DK3052101T3 (da) * | 2013-10-04 | 2019-12-16 | Prolynx Llc | Konjugater af sn-38 med langsom frigivelse |
-
2014
- 2014-10-03 DK DK14796322.7T patent/DK3052101T3/da active
- 2014-10-03 JP JP2016520004A patent/JP6473145B2/ja active Active
- 2014-10-03 AU AU2014331591A patent/AU2014331591B2/en active Active
- 2014-10-03 MX MX2016004299A patent/MX371201B/es active IP Right Grant
- 2014-10-03 US US15/026,579 patent/US10016411B2/en active Active
- 2014-10-03 EP EP14796322.7A patent/EP3052101B1/en active Active
- 2014-10-03 CA CA2925132A patent/CA2925132C/en active Active
- 2014-10-03 ES ES14796322T patent/ES2759905T3/es active Active
- 2014-10-03 TW TW103134678A patent/TWI716342B/zh active
- 2014-10-03 SG SG10201811365RA patent/SG10201811365RA/en unknown
- 2014-10-03 WO PCT/US2014/059146 patent/WO2015051307A1/en not_active Ceased
- 2014-10-03 SG SG11201602258WA patent/SG11201602258WA/en unknown
- 2014-10-03 KR KR1020167011936A patent/KR102320753B1/ko active Active
- 2014-10-03 CN CN201480062543.4A patent/CN106061483B/zh active Active
- 2014-10-03 BR BR112016007410-6A patent/BR112016007410B1/pt active IP Right Grant
-
2018
- 2018-06-14 US US16/009,078 patent/US10342792B2/en active Active
- 2018-11-01 AU AU2018256608A patent/AU2018256608A1/en not_active Abandoned
-
2019
- 2019-01-24 JP JP2019010029A patent/JP6842479B2/ja active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP6473145B2 (ja) | 2019-02-20 |
| JP2016531895A (ja) | 2016-10-13 |
| JP2019104739A (ja) | 2019-06-27 |
| ES2759905T3 (es) | 2020-05-12 |
| AU2014331591A1 (en) | 2016-05-19 |
| JP6842479B2 (ja) | 2021-03-17 |
| CN106061483B (zh) | 2021-01-08 |
| MX371201B (es) | 2020-01-22 |
| SG11201602258WA (en) | 2016-04-28 |
| BR112016007410A2 (pt) | 2017-08-01 |
| TWI716342B (zh) | 2021-01-21 |
| MX2016004299A (es) | 2016-10-04 |
| KR102320753B1 (ko) | 2021-11-02 |
| BR112016007410A8 (pt) | 2020-02-27 |
| US10016411B2 (en) | 2018-07-10 |
| EP3052101A1 (en) | 2016-08-10 |
| AU2018256608A1 (en) | 2018-11-22 |
| EP3052101B1 (en) | 2019-11-20 |
| US20160243106A1 (en) | 2016-08-25 |
| CA2925132C (en) | 2021-11-30 |
| KR20160065203A (ko) | 2016-06-08 |
| WO2015051307A1 (en) | 2015-04-09 |
| TW201601759A (zh) | 2016-01-16 |
| US10342792B2 (en) | 2019-07-09 |
| CN106061483A (zh) | 2016-10-26 |
| CA2925132A1 (en) | 2015-04-09 |
| AU2014331591B2 (en) | 2018-08-16 |
| BR112016007410B1 (pt) | 2022-07-19 |
| US20180289695A1 (en) | 2018-10-11 |
| DK3052101T3 (da) | 2019-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG10201811365RA (en) | Slow-release conjugates of sn-38 | |
| EP3065808A4 (en) | Devices and methods for continuous drug delivery via the mouth | |
| IL278183A (en) | Proton-binding polymers for oral administration | |
| MY170719A (en) | Antibody-drug conjugates | |
| NZ725480A (en) | Anti-ptk7 antibody-drug conjugates | |
| HK1216083A1 (zh) | 经动脉的药物递送 | |
| EP3077006A4 (en) | Polymer-carbohydrate conjugates for drug delivery technology | |
| TW201613641A (en) | Anti-CD22 antibody-drug conjugates and methods of using thereof | |
| IL240434A0 (en) | Bicyclo 3,2-benzodiazepines and spirocyclically converted 3,2-benzodiazepines | |
| PL3478323T3 (pl) | Rozszczepialne koniugaty polimer-lek | |
| EP3025527A4 (en) | Generating geofences | |
| WO2014169007A3 (en) | Combination therapeutic nanoparticles | |
| EP3161489A4 (en) | Markers and therapeutic indicators for glioblastoma multiforme (gbm) | |
| EP2987404A4 (en) | INJECTION DEVICE FOR POWDERED MEDICAMENTS AND INJECTION METHOD FOR POWDERY MEDICAMENTS | |
| EP3581205A3 (en) | Product and method for treating diarrhea | |
| MX2016006087A (es) | Formulaciones de desintegracion rapida y metodos de uso. | |
| EP3082903A4 (en) | Wearable medication administration device | |
| IL269028A (en) | Boronized multifunctional drug-targeting conjugates, their uses and methods of preparation | |
| IN2013MU02015A (https=) | ||
| IN2013MU01226A (https=) | ||
| UA84204U (ru) | Способ иммунокоррекции больных ветряной оспой с наличием иммунодефицитных состояний | |
| UA92247U (ru) | ПРИМЕНЕНИЕ МЕТИЛОВОГО ЭСТЕРА 5-МЕТИЛ-4-ОКСО-3,4-ДИГИДРОТИЕНО[2,3-d]ПИРИМИДИН-6-КАРБОНОВОЙ КИСЛОТЫ КАК АНАЛЬГЕТИЧЕСКОГО И ПРОТИВОВОСПАЛИТЕЛЬНОГО СРЕДСТВА | |
| IN2013CH02437A (https=) | ||
| IN2013MU03310A (https=) | ||
| UA99990U (ru) | 2-амино-4-метил-9-(2,5-диметоксифенил)-7-оксо-3-циано-6,7,8,9-тетрагидропиридо[3',2':4,5]тиено[3,2-b]пиридин |